|1.||Marakos, Panagiotis: 1 article (05/2011)|
|2.||Kostakis, Ioannis K: 1 article (05/2011)|
|3.||Tsitsilonis, Ourania E: 1 article (05/2011)|
|4.||Christodoulou, Antonios: 1 article (05/2011)|
|5.||Pouli, Nicole: 1 article (05/2011)|
|6.||Trougakos, Ioannis P: 1 article (05/2011)|
|7.||Kourafalos, Vassilios: 1 article (05/2011)|
|8.||Denny, William A: 1 article (03/2006)|
|9.||Yin, Catherine C: 1 article (03/2006)|
|10.||Terry, Caitlin E: 1 article (03/2006)|
01/01/1973 - "Therapeutic efficacy of compound C-283 in patients with mammary carcinoma."
01/01/1972 - "Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. "
01/01/1972 - "Biochemical blood studies in patients with ovarian carcinoma treated with C-283. "
01/01/1971 - "Biochemical blood studies in patients with carcinoma of the ovaries during treatment with preparation C-283. "
01/01/1983 - "Ledakrin in treatment of patients with carcinoma of the lung."
08/01/2002 - "In this study, cell cycle perturbations, effects on DNA synthesis and the cell death process initiated by Nitracrine were studied in murine leukemia L1210 cells. "
01/01/1994 - "Thiol dependent inhibition of mouse leukemia L1210 DNA topoisomerase I by nitracrine."
11/01/1987 - "For seven new methoxy and/or nitro derivatives of acridine antitumor drugs, nitracrine and amsacrine, biological activity in a few in vitro tests, as well as activity against experimental murine tumors Sarcoma-180 and Leukemia L1210 were investigated. "
11/15/1989 - "Ledakrin [1-nitro-9-(3'-dimethylamino-N-propylamino)acridine], an antitumor drug of the 1-nitro-9-aminoacridine family, was able to induce DNA-protein crosslinks in intact L1210 leukemia cells, as demonstrated by the potassium-dodecyl sulfate precipitation technique. "
05/15/2011 - "The synthesis of a number of new benzothiopyrano[4,3,2-cd]isoindole aminoderivatives designed as structural analogues of the key metabolite of the anticancer agent Ledacrine (nitracrine) and their in vitro cytotoxic activity evaluation against HCT-116, MES-SA, and MES-SA/Dx cancer cell lines is reported. "
06/21/1996 - "The parent compound 2 was selectively toxic to hypoxic cells in KHT tumors in vivo and clearly superior to nitracrine itself (although only at doses which would eventually be lethal to the host). "
05/01/1990 - "II. Features of nitracrine analogs for high anti-tumor activity and selectivity on mice, searched by PCA and MRA methods."
04/01/1990 - "Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors."
01/01/1989 - "Such stabilization may enhance the therapeutic utility of the nitroacridines in cancer therapy since rapid metabolism of nitracrine appears to prevent its activity against hypoxic cells in solid tumors."
05/01/1990 - "In an attempt to modulate the degree of hypoxia selectivity among this class of compounds, we have studied a series of side-chain analogues of nitracrine. "
05/01/1990 - "The nitroacridine derivative nitracrine is a potent hypoxia-selective cytotoxin for mammalian cells in culture. "
05/01/1990 - "4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis"."
05/01/1989 - "To determine whether it is possible to separate antitumour and mutagenic properties in the nitracrine series, a number of 4-substituted derivatives of the hypoxia-selective drug nitracrine have been evaluated for their mutagenic effects at three loci in several strains of Salmonella typhimurium differing in DNA-repair capacity (uvrB, recA, plasmid pKM101). "
01/01/1989 - "Nevertheless, comparison of the kinetics of the killing of AA8 cells under hypoxia suggests that some metabolic stabilization of the compounds can be achieved by the use of electron-donating substituents, with such compounds retaining the hypoxia-selective toxicity of nitracrine in cell culture. "
08/17/1993 - "The cytotoxic effect of and DNA damage induced by nitracrine were measured in two sublines of mouse lymphoma L5178Y, LY-R (resistant to ionizing radiation) and LY-S (sensitive to ionizing radiation). "
01/01/1992 - "DNA-protein cross-linking induced by nitracrine in two strains of mouse lymphoma L5178Y cells."
01/01/1980 - "The response to nitracrine, 1-nitro-9-[3'(N,N-dimethyl)aminopropyl] aminoacridine, an anticancer agent, was examined in two strains of murine lymphoma L5178Y inversely cross-sensitive to X-rays and UV light. "
|1.||DNA (Deoxyribonucleic Acid)
|2.||Nitracrine (C 283)
|5.||A-Form DNA (A-DNA)
|1.||Drug Therapy (Chemotherapy)